724 related articles for article (PubMed ID: 31293342)
21. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.
Sikkema M; Looman CW; Steyerberg EW; Kerkhof M; Kastelein F; van Dekken H; van Vuuren AJ; Bode WA; van der Valk H; Ouwendijk RJ; Giard R; Lesterhuis W; Heinhuis R; Klinkenberg EC; Meijer GA; ter Borg F; Arends JW; Kolkman JJ; van Baarlen J; de Vries RA; Mulder AH; van Tilburg AJ; Offerhaus GJ; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD
Am J Gastroenterol; 2011 Jul; 106(7):1231-8. PubMed ID: 21577245
[TBL] [Abstract][Full Text] [Related]
22. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
[TBL] [Abstract][Full Text] [Related]
23. Lack of incremental effect of histamine receptor antagonists over proton pump inhibitors on the risk of neoplastic progression in patients with Barrett's esophagus: a cohort study.
Thota PN; Hajifathalian K; Benjamin T; Runkana A; Lopez R; Sanaka MR
J Dig Dis; 2017 Mar; 18(3):143-150. PubMed ID: 28188977
[TBL] [Abstract][Full Text] [Related]
24. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.
Desai M; Lieberman DA; Kennedy KF; Hamade N; Thota P; Parasa S; Gorrepati VS; Bansal A; Gupta N; Gaddam S; Young PE; Mathur S; Moawad FJ; Cash BD; Sampliner R; Vargo JJ; Falk GW; Sharma P
Gastrointest Endosc; 2019 Feb; 89(2):257-263.e3. PubMed ID: 30342028
[TBL] [Abstract][Full Text] [Related]
25. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
[TBL] [Abstract][Full Text] [Related]
26. Clinical and pathological predictors of failure of endoscopic therapy for Barrett's related high-grade dysplasia and early esophageal adenocarcinoma.
Shimamura Y; Iwaya Y; Kobayashi R; Rodriguez de Santiago E; Muwanwella N; Raftopoulos S; Mosko JD; May GR; Kandel G; Kortan P; Marcon N; Teshima CW
Surg Endosc; 2021 Oct; 35(10):5468-5479. PubMed ID: 32989547
[TBL] [Abstract][Full Text] [Related]
27. Young Adults With Esophageal Adenocarcinoma Present With More Advanced Stage Tumors and Have Shorter Survival Times.
Sawas T; Manrique GC; Iyer PG; Wang KK; Katzka DA
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1756-1762. PubMed ID: 30267861
[TBL] [Abstract][Full Text] [Related]
28. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
29. Predictors of recurrence of dysplasia or cancer in patients with dysplastic Barrett's esophagus following complete eradication of dysplasia: a single-center retrospective cohort study.
Kobayashi R; Calo NC; Marcon N; Iwaya Y; Shimamura Y; Honda H; Streutker C; Mosko J; May G; Teshima C
Surg Endosc; 2022 Jul; 36(7):5041-5048. PubMed ID: 34750708
[TBL] [Abstract][Full Text] [Related]
30. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
Wani S; Rubenstein JH; Vieth M; Bergman J
Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
[TBL] [Abstract][Full Text] [Related]
32. Clinical Outcomes Following Recurrence of Intestinal Metaplasia After Successful Treatment of Barrett's Esophagus With Radiofrequency Ablation.
Guthikonda A; Cotton CC; Madanick RD; Spacek MB; Moist SE; Ferrell K; Dellon ES; Shaheen NJ
Am J Gastroenterol; 2017 Jan; 112(1):87-94. PubMed ID: 27725648
[TBL] [Abstract][Full Text] [Related]
33. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
34. Barrett's oesophagus: Current controversies.
Amadi C; Gatenby P
World J Gastroenterol; 2017 Jul; 23(28):5051-5067. PubMed ID: 28811703
[TBL] [Abstract][Full Text] [Related]
35. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
Endzinas Z; Mickevicius A; Kiudelis M
Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
[TBL] [Abstract][Full Text] [Related]
36. LOW PREVALENCE OF BARRETT'S ESOPHAGUS IN A RISK AREA FOR ESOPHAGEAL CANCER IN SOUTH OF BRAZIL.
DE Carli DM; Araujo AF; Fagundes RB
Arq Gastroenterol; 2017 Dec; 54(4):305-307. PubMed ID: 28954045
[TBL] [Abstract][Full Text] [Related]
37. Cryotherapy and Radiofrequency Ablation for Eradication of Barrett's Esophagus with Dysplasia or Intramucosal Cancer.
Thota PN; Arora Z; Dumot JA; Falk G; Benjamin T; Goldblum J; Jang S; Lopez R; Vargo JJ
Dig Dis Sci; 2018 May; 63(5):1311-1319. PubMed ID: 29524114
[TBL] [Abstract][Full Text] [Related]
38. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
39. Symptoms and endoscopic features at barrett's esophagus diagnosis: implications for neoplastic progression risk.
Coleman HG; Bhat SK; Murray LJ; McManus DT; O'Neill OM; Gavin AT; Johnston BT
Am J Gastroenterol; 2014 Apr; 109(4):527-34. PubMed ID: 24589668
[TBL] [Abstract][Full Text] [Related]
40. Adherence to clinical guidelines for Barrett's esophagus.
Holmberg D; Ness-Jensen E; Mattsson F; Lagergren J
Scand J Gastroenterol; 2019 Aug; 54(8):945-952. PubMed ID: 31314608
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
